Equities Analysts Set Expectations for RARE Q1 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Wedbush cut their Q1 2025 EPS estimates for Ultragenyx Pharmaceutical in a research report issued on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of ($1.09) per share for the quarter, down from their prior estimate of ($1.06). Wedbush has a "Neutral" rating and a $48.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical's Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.78) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.81) EPS, FY2028 earnings at $1.91 EPS and FY2029 earnings at $3.20 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million.

Several other brokerages have also recently commented on RARE. JPMorgan Chase & Co. raised their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. HC Wainwright reaffirmed a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Canaccord Genuity Group increased their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Finally, Piper Sandler decreased their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Stock Up 4.1 %

Shares of Ultragenyx Pharmaceutical stock traded up $1.47 on Friday, hitting $37.38. The stock had a trading volume of 356,659 shares, compared to its average volume of 811,497. The stock has a market cap of $3.51 billion, a price-to-earnings ratio of -5.90 and a beta of 0.61. The business's 50 day moving average is $38.10 and its two-hundred day moving average is $43.93. Ultragenyx Pharmaceutical has a twelve month low of $29.59 and a twelve month high of $60.37.

Insider Activity

In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the completion of the sale, the chief accounting officer now directly owns 50,265 shares of the company's stock, valued at approximately $2,116,156.50. The trade was a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares in the company, valued at $4,289,227.60. This represents a 1.65 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 124,643 shares of company stock worth $5,256,268. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock worth $4,802,000 after buying an additional 76,150 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after acquiring an additional 294 shares during the period. Geode Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 4.4% in the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock worth $87,296,000 after purchasing an additional 65,623 shares during the last quarter. KBC Group NV boosted its position in Ultragenyx Pharmaceutical by 2,275.8% in the fourth quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company's stock worth $2,567,000 after purchasing an additional 58,442 shares during the last quarter. Finally, abrdn plc grew its stake in Ultragenyx Pharmaceutical by 25.2% in the 4th quarter. abrdn plc now owns 317,125 shares of the biopharmaceutical company's stock valued at $13,341,000 after purchasing an additional 63,821 shares during the period. 97.67% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.